An interventional study of Autologous platelet rich plasma gel and Placebo in Diabetic Foot Ulcers, sponsored by Regen Lab SA. Status unknown at 1 site in United States. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2020-10-08.
Sponsored by Regen Lab SA · Not applicable, Interventional, and Treatment
Autologous platelet-rich plasma (PRP) gel was reported to have very good outcomes in the treatment of foot ulcers in pilot studies and retrospective uncontrolled trials. Therefore, a larger randomized, placebo-controlled clinical trial will be useful to determine whether platelet-rich plasma is safe and effective for the treatment of diabetic foot ulcers (DFU).
Evaluate the safety and efficacy of RegenKit autologous PRP Gel for the treatment of diabetic foot ulcer is a randomized, placebo controlled, blind-assessor study. One hundred and seventy four patients will be treated, 87 patients receiving treatment arm and 87 patients receiving placebo. The primary endpoint is to evaluate proportion of patients with complete wound closure at week 16 when treated with autologous platelet rich plasma gel compared to the proportion of control (saline gel) treated patients with complete wound closure at the same time-point.
1,054 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.
This study's planned enrollment of 192 is above the median of 60 across 826 interventional studies indexed under Diabetic Foot.
Browse Diabetic Foot studies →Regen Lab SA is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients having adequate circulation to the foot as documented by either:
i)Toe Brachial Index (TBI) equal to or greater than 0.50 or, ii)TBI is not available (toe is absent, wounds are present, or investigative site cannot perform a TBI), a Doppler waveform in the posterior tibial or dorsalis pedis arteries at the ankle consistent with adequate flow in the foot (biphasic or triphasic) and other diagnostic confirmation of adequate flow (e.g duplex imaging or normal pulse volume recording)
Exclusion Criteria
Autologous platelet rich plasma gel
Device: Autologous platelet rich plasma gel
Saline gel
Device: Placebo
PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
Proportion of patients with complete wound closure
Proportion of patients with complete wound closure at week 16 when treated with autologous platelet rich plasma gel compared to the proportion of control (saline gel)-treated patients with complete wound closure at the same time-point.
Time frame: 16 weeks
Plan to share: Yes — The Institution and the Principal Investigator are free to publish, present, or use any data and results arising out of this Study, provided that such publication does not disclose any of Sponsor's Confidential Information. Sponsor shall be able to present data and results at symposia, national or regional professional meetings, and publish in journals, theses or dissertations, or otherwise of its own choosing. In the event that the Principal Investigator fails to submit a formal academic publication within twelve (12) months following completion of the Study, the Sponsor is entitled to prepare a publication based on the data and results. Such proposed publication will be submitted to the Institution for review and comment at the least thirty (30) calendar days before submission for publication.
No publications or documents are linked to this record.
This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regen Lab SA